Differential Diagnosis of Parkinsonism

Parkinsonism — defined as bradykinesia in combination with rest tremor, rigidity, or both — is a clinical syndrome with multiple etiologies, not a single disease. While idiopathic Parkinson's disease (PD) accounts for approximately 75–80% of cases, 10–25% of clinically diagnosed PD is reclassified at autopsy. Accurate differential diagnosis is essential because alternative diagnoses carry different prognoses, treatment responses, and clinical trajectories. The MDS Clinical Diagnostic Criteria (Postuma et al., 2015) embed the differential diagnosis into their structure — red flags and absolute exclusion criteria are designed to identify non-PD parkinsonism. This article provides a structured approach to the differential diagnosis of parkinsonism, focusing on the clinical features, investigations, and distinguishing characteristics of each major alternative.

Approach to the Patient with Parkinsonism

The clinical evaluation of parkinsonism should systematically address five key questions: (1) Is parkinsonism truly present? (bradykinesia must be confirmed — not just slowness from weakness, pain, or depression); (2) Is the pattern consistent with PD? (asymmetric onset, rest tremor, clear levodopa response); (3) Are there red flags for an alternative diagnosis? (4) Are there absolute exclusion criteria for PD? (5) Are there secondary causes (drugs, structural lesions, metabolic disease)?

The tempo of progression is a critical diagnostic clue. PD typically progresses gradually over years; rapid progression to wheelchair (<5 years), early severe autonomic failure, or early cognitive decline should raise suspicion for MSA, PSP, or DLB. Symmetry at onset, axial predominance, and failure to respond to adequate levodopa challenge (at least 600–1000 mg/day for ≥1–2 months) are strong pointers away from PD.

Atypical Parkinsonism

The atypical parkinsonian syndromes — MSA, PSP, CBS, and DLB — are covered in dedicated articles. Below is a summary of the distinguishing features relevant to differential diagnosis.

Multiple System Atrophy (MSA)

MSA presents as a combination of parkinsonism, cerebellar ataxia, and/or autonomic failure. Two clinical subtypes are recognized: MSA-P (parkinsonian predominant) and MSA-C (cerebellar predominant). Key distinguishing features from PD include: early severe autonomic failure (orthostatic hypotension, urinary incontinence/retention, erectile dysfunction — within the first 5 years, more severe than typical PD autonomic dysfunction), poor or waning levodopa response (though up to 30% have an initial partial response), cerebellar signs (gait ataxia, limb ataxia, scanning speech), inspiratory stridor (vocal cord dysfunction — a red flag), anterocollis, and rapid progression (median survival 6–10 years from onset). MRI may show the "hot cross bun" sign (pontine cruciform hyperintensity in MSA-C) and putaminal atrophy with a lateral slit hyperintensity. α-Synuclein SAA is positive in MSA but with lower sensitivity than PD (~85–90% vs >95%)⁽¹⁾.

Progressive Supranuclear Palsy (PSP)

PSP is a tauopathy that classically presents as PSP-Richardson syndrome (the most common phenotype): early falls (typically backward, within the first year), vertical supranuclear gaze palsy (initially slowed vertical saccades, progressing to complete downgaze limitation), axial rigidity greater than limb rigidity, pseudobulbar affect, frontal cognitive-behavioral syndrome, and poor levodopa response. Less common phenotypes include PSP-P (PSP-parkinsonism, which can closely mimic PD with asymmetric onset and partial levodopa response, making early differentiation particularly challenging) and PSP-CBS (corticobasal syndrome overlap). MRI shows the "hummingbird sign" (midbrain atrophy on sagittal imaging) and "morning glory sign" (midbrain atrophy on axial imaging). DaT-SPECT is abnormal but cannot distinguish PSP from PD. α-Synuclein SAA is negative⁽¹⁾.

Corticobasal Syndrome (CBS)

CBS is defined by the combination of asymmetric parkinsonism with prominent cortical features: limb apraxia (ideomotor, especially progressive difficulty with learned motor tasks), cortical sensory loss (agraphesthesia, astereognosis), alien limb phenomenon, myoclonus, and dystonia. The parkinsonism is typically rigid-akinetic with minimal tremor and poor levodopa response. CBS is a clinical syndrome with heterogeneous pathology: only ~50% have corticobasal degeneration (CBD) at autopsy; others have PSP, AD, or frontotemporal lobar degeneration pathology. Asymmetric cortical atrophy (frontoparietal, contralateral to the clinically affected side) is the characteristic imaging finding⁽¹⁾.

Dementia with Lewy Bodies (DLB)

DLB shares Lewy body pathology with PD but is distinguished by the temporal relationship of cognitive and motor symptoms. By convention, PDD applies when dementia develops ≥1 year after established motor PD; DLB applies when dementia precedes or occurs within 1 year of parkinsonism (the "1-year rule"). Core clinical features of DLB include: fluctuating cognition (marked variations in attention and alertness), recurrent formed visual hallucinations (typically early and detailed), REM sleep behavior disorder, and spontaneous parkinsonism. DLB patients are exquisitely sensitive to antipsychotics — even low-dose risperidone or haloperidol can cause life-threatening parkinsonism, sedation, and autonomic instability. α-Synuclein SAA is positive. DaT-SPECT is abnormal. The distinction between DLB and PDD is primarily clinical and temporal, not pathologic⁽¹⁾.

Drug-Induced Parkinsonism

Drug-induced parkinsonism (DIP) is the most important reversible cause of parkinsonism and the second most common cause overall. It is an absolute exclusion criterion in the MDS diagnostic criteria for PD. Any drug that blocks dopamine receptors or depletes dopamine can cause DIP:

Most common offenders: Typical antipsychotics (haloperidol, chlorpromazine), atypical antipsychotics (risperidone, olanzapine — quetiapine and clozapine are least likely), antiemetics (metoclopramide, prochlorperazine, promethazine), and dopamine depleters (tetrabenazine, valbenazine, deutetrabenazine — used for tardive dyskinesia). Less recognized causes: Calcium channel blockers (flunarizine, cinnarizine — common in some countries), valproate, lithium, and some SSRIs.

Clinical features that suggest DIP over PD: bilateral symmetric onset, prominent orobuccolingual involvement, associated tardive dyskinesia, temporal relationship to medication initiation (usually within weeks to months), and normal DaT-SPECT. However, the distinction is complicated by the fact that up to 30% of DIP patients have underlying subclinical PD unmasked by the offending drug — these patients will have abnormal DaT-SPECT and may not fully recover after drug withdrawal.

Management: Discontinue the offending agent when possible (recovery may take weeks to months). If an antipsychotic is necessary, switch to quetiapine or clozapine. Anticholinergics (benztropine, trihexyphenidyl) can provide partial symptomatic relief. Do not use levodopa or dopamine agonists (they are ineffective when dopamine receptors are blocked).

Vascular Parkinsonism

Vascular parkinsonism (VP) accounts for approximately 3–5% of parkinsonism and results from cerebrovascular disease affecting the basal ganglia, thalamus, or frontal-subcortical white matter circuits. The classic presentation is "lower-body parkinsonism": prominent gait impairment (short-stepped, magnetic gait), postural instability, and lower-extremity rigidity/bradykinesia with relatively preserved upper-extremity function. Rest tremor is typically absent or minimal. Onset may be acute (post-stroke) or stepwise, and progression follows a vascular pattern rather than the gradual progression of PD.

Key distinguishing features: Lower-body predominance, bilateral symmetric involvement, minimal or absent rest tremor, poor or absent levodopa response (though a subset has partial response), history of stroke/TIA or vascular risk factors, pseudobulbar affect, and urinary incontinence early in the course. MRI shows confluent white matter hyperintensities, lacunar infarcts in the basal ganglia, or strategic strokes. DaT-SPECT is typically normal or shows a pattern different from PD (e.g., bilateral symmetric loss rather than the asymmetric putaminal gradient characteristic of PD).

Management focuses on vascular risk factor modification (hypertension, diabetes, hyperlipidemia, smoking cessation). A levodopa trial (up to 600–1000 mg/day for 1–2 months) should be attempted, as a subset of patients derive meaningful benefit. Physical therapy targeting gait and balance is essential.

Essential Tremor vs Tremor-Dominant PD

Essential tremor (ET) and tremor-dominant PD (TDPD) are among the most commonly confused diagnoses. The distinction matters for prognosis, treatment, and counseling. While the classic features are well-defined, overlap cases ("ET plus," possible PD with tremor) can be diagnostically challenging.

Re-emergent tremor is a common diagnostic pitfall: in TDPD, a rest tremor may re-emerge after the patient holds their arms outstretched for several seconds (after an initial tremor-free latency period). This re-emergent postural tremor is distinct from the immediate-onset action tremor of ET and suggests underlying PD. When diagnostic uncertainty persists, DaT-SPECT is the most useful confirmatory test.

Other Diagnostic Considerations

Normal Pressure Hydrocephalus

NPH presents with the classic triad of gait disturbance (magnetic, wide-based, shuffling), cognitive impairment (subcortical pattern), and urinary incontinence. The gait can mimic lower-body parkinsonism, and NPH may coexist with PD in elderly patients. CT/MRI shows ventriculomegaly disproportionate to cortical atrophy (Evans' index >0.3). The diagnostic and therapeutic test is large-volume lumbar puncture (30–50 mL) with pre- and post-tap gait assessment.

Wilson Disease

Wilson disease should be considered in any patient presenting with parkinsonism or dystonia under age 50. It is an autosomal recessive copper metabolism disorder (ATP7B mutations) causing hepatic and neurological damage. Neurological features include parkinsonism, dystonia (frequently orofacial), tremor (including a characteristic "wing-beating" proximal tremor), cerebellar ataxia, and psychiatric manifestations. Diagnosis: slit-lamp examination for Kayser-Fleischer rings, low serum ceruloplasmin (<20 mg/dL), elevated 24-hour urinary copper, and MRI showing the "face of the giant panda" sign in the midbrain. Treatment with copper chelators (penicillamine, trientine) or zinc supplementation is disease-modifying if started early.

Functional (Psychogenic) Movement Disorders

Functional parkinsonism is increasingly recognized as a diagnostic consideration, particularly in patients with normal DaT-SPECT. Clinical features suggestive of functional parkinsonism include: inconsistency (variability in severity with distraction or attention), incongruence with known neurologic patterns, sudden onset, rapid fluctuations unrelated to medication timing, distractibility of symptoms during examination, "give-way" resistance on tone testing rather than true rigidity, and entrainment of tremor (tremor frequency shifts to match a voluntary rhythm in the contralateral limb). DaT-SPECT is normal. Positive diagnostic signs (demonstrating internal inconsistency) are preferred over exclusion of organic disease.

Dopa-Responsive Dystonia

DRD (Segawa disease, GTP cyclohydrolase 1 deficiency) presents in childhood or adolescence with dystonia affecting gait and limbs, with marked diurnal fluctuation (worsening toward evening). It can be mistaken for young-onset PD due to its dramatic levodopa response. Distinguishing features: childhood onset, diurnal variation, dystonia as the predominant feature (rather than bradykinesia), normal DaT-SPECT, and sustained low-dose levodopa response without developing motor complications over decades. GCH1 gene testing confirms the diagnosis⁽¹⁾.

SWEDD & Biomarker-Negative Parkinsonism

Scans Without Evidence of Dopaminergic Deficit (SWEDD) describes patients clinically diagnosed with PD who have a normal DaT-SPECT. This occurs in 5–15% of patients enrolled in PD clinical trials. Long-term follow-up studies show that the majority of SWEDD patients are reclassified on follow-up — most commonly as essential tremor, dystonic tremor, or functional movement disorders. A minority have early PD with DaT-SPECT not yet abnormal (DaT-SPECT becomes positive after ~50% nigrostriatal loss).

In the NSD-ISS biological framework, patients who are both SAA-negative and DaT-negative are classified as "not NSD" — they do not have neuronal α-synuclein disease. The PPMI cohort data showed that ~7% of clinically diagnosed sporadic PD patients are SAA-negative, raising the possibility of non-synuclein parkinsonism or misdiagnosis. This has implications for clinical trial enrollment and for the eventual clinical application of biological classification systems⁽¹⁾.

Diagnostic Comparison Table

*DaT-SPECT may be abnormal in DIP when underlying subclinical PD is unmasked by the offending drug (~30% of cases).